论文部分内容阅读
目的观察131I治疗105例甲状腺功能亢进伴2型糖尿病患者的临床疗效。方法回顾性分析2011年9月至2013年9月收治的105例甲状腺功能亢进伴2型糖尿病患者的临床资料。结果观察组患者的总有效率为89.1%(49/55),对照组为74%(37/50),差异有统计学意义(P<0.05);治疗后观察组患者的TT3、TT4、FT3、FT4、TSH、FPG、2hPG、HbAlc水平均明显比对照组低(P<0.05);治疗后9、12、24个月观察组患者的甲状腺功能减低发生率及甲状腺功能亢进症复发率均明显比对照组低(P<0.05)。结论131I治疗甲状腺功能亢进伴2型糖尿病患者的临床疗效良好。
Objective To observe the clinical efficacy of 131I in the treatment of 105 patients with hyperthyroidism and type 2 diabetes mellitus. Methods The clinical data of 105 patients with hyperthyroidism and type 2 diabetes mellitus were retrospectively analyzed from September 2011 to September 2013. Results The total effective rate was 89.1% (49/55) in the observation group and 74% (37/50) in the control group, with significant difference (P <0.05). The TT3, TT4 and FT3 in the observation group , FT4, TSH, FPG, 2hPG and HbAlc in the observation group were significantly lower than those in the control group (P <0.05). At 9, 12 and 24 months after treatment, the incidences of hypothyroidism and the recurrence rate of hyperthyroidism in the observation group were significantly higher Lower than the control group (P <0.05). Conclusion 131I treatment of hyperthyroidism with type 2 diabetes patients with good clinical efficacy.